Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories. It also provides breast implants and tissue expanders; RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis; ocular implants; and Kybella, a non-surgical treatment for submental fullness. In addition, the company develops therapies for non-alcoholic steatohepatitis and other liver diseases; treatments for neurodegenerative disorders, including Alzheimer's disease; small molecule therapeutics that target inflammatory and fibrotic diseases; and delivery system and botulinum toxin-based prescription products. It has collaboration, option, and license agreement with Lyndra, Inc.; strategic alliance and option agreement with Editas Medicine, Inc.; and licensing agreements with Assembly Biosciences, Inc. MedImmune, and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone862-261-7000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$15.94 billion
Profitability
Miscellaneous
Employees17,800
OptionableOptionable
Allergan (NYSE:AGN) Frequently Asked Questions
What is Allergan's stock symbol?
Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."
How often does Allergan pay dividends? What is the dividend yield for Allergan?
Allergan declared a quarterly dividend on Friday, October 26th. Stockholders of record on Tuesday, November 13th will be paid a dividend of $0.72 per share on Friday, December 14th. This represents a $2.88 annualized dividend and a dividend yield of 1.80%. The ex-dividend date of this dividend is Friday, November 9th. View Allergan's Dividend History.
How will Allergan's stock buyback program work?
Allergan announced that its Board of Directors has initiated a share buyback plan on Tuesday, September 26th 2017, which allows the company to buyback $2,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to purchase up to 2.8% of its shares through open market purchases. Shares buyback plans are often an indication that the company's board of directors believes its stock is undervalued.
How were Allergan's earnings last quarter?
Allergan plc (NYSE:AGN) announced its quarterly earnings data on Tuesday, October, 30th. The company reported $4.25 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $4.04 by $0.21. The firm had revenue of $3.91 billion for the quarter, compared to analyst estimates of $3.89 billion. Allergan had a return on equity of 8.44% and a net margin of 14.50%. The company's revenue for the quarter was down 3.0% on a year-over-year basis. During the same period in the prior year, the firm earned $4.15 earnings per share. View Allergan's Earnings History.
When is Allergan's next earnings date?
How can I listen to Allergan's earnings call?
Allergan will be holding an earnings conference call on Tuesday, January 29th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8772517980.
What guidance has Allergan issued on next quarter's earnings?
Allergan updated its FY18 earnings guidance on Tuesday, October, 30th. The company provided earnings per share (EPS) guidance of $16.20-16.60 for the period, compared to the Thomson Reuters consensus EPS estimate of $16.38. The company issued revenue guidance of $15.55-15.7 billion, compared to the consensus revenue estimate of $15.63 billion.Allergan also updated its FY 2018 guidance to $16.20-16.60 EPS.
What price target have analysts set for AGN?
21 brokerages have issued twelve-month price targets for Allergan's stock. Their predictions range from $164.00 to $265.00. On average, they anticipate Allergan's stock price to reach $211.2778 in the next twelve months. This suggests a possible upside of 31.9% from the stock's current price. View Analyst Price Targets for Allergan.
What is the consensus analysts' recommendation for Allergan?
21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergan in the last year. There are currently 4 hold ratings and 17 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Allergan.
What are Wall Street analysts saying about Allergan stock?
Here are some recent quotes from research analysts about Allergan stock:
- 1. According to Zacks Investment Research, "Allergan’s products like Botox and Linzess and new products such as Viberzi, Namzaric and Vraylar support sales. It also boasts a strong branded pipeline. Biosimilars also represent significant opportunity. However, while we remain optimistic about the company’s growth prospects, Allergan faces loss of exclusivity for many key products. While generic versions of Alzheimer’s treatment, Namenda XR and Estrace cream have been launched, that of blockbuster dry-eye drug, Restasis, is expected to be launched soon. Sales of these products are expected to decline significantly with the introduction of generics. Also, new competition for key growth drivers, Botox, Restasis and Linzess, is a concern. Particularly, the entry of CGRP antibodies in 2018 may have a negative impact on sales of Botox Therapeutics, mainly for the chronic migraine indication. Allergan’s shares have underperformed the industry in the past three months." (1/3/2019)
- 2. Cantor Fitzgerald analysts commented, "We rate AGN Neutral and have a 12-month price target of $180. We think that Allergan is one the highest-quality and most-innovative companies in the Pharma industry. That said, we don’t see a lot of upside to consensus expectations in the near term, which is why we are on the sidelines for now. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $180." (9/14/2018)
- 3. Mizuho analysts commented, "We note that Mylan has invalidated Restasis patents, and Allergan mgmt. noted that two other generic manufacturers (Teva and Akorn that have not settled) could also launch Restasis generics if their applications are FDA-approved. We know that Allergan separately entered into five other generic settlements, according to its 1Q:18 10-Q filing. No news from Mylan or the others would be good news to Allergan, in our view." (7/30/2018)
Has Allergan been receiving favorable news coverage?
News coverage about AGN stock has been trending somewhat positive recently, according to InfoTrie. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Allergan earned a news impact score of 0.9 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an impact on the stock's share price in the immediate future.
Who are some of Allergan's key competitors?
Some companies that are related to Allergan include Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Eli Lilly And Co (LLY), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), Sanofi (SNY), GlaxoSmithKline (GSK), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Shire (SHPG), Vertex Pharmaceuticals (VRTX) and Regeneron Pharmaceuticals (REGN).
Who are Allergan's key executives?
Allergan's management team includes the folowing people:
- Mr. Brenton L. Saunders, Chairman, Pres & CEO (Age 48)
- Mr. William Meury, Exec. VP & Chief Commercial Officer (Age 50)
- Dr. C. David Nicholson, Exec. VP and Chief R&D Officer (Age 63)
- Mr. Matthew M. Walsh, Exec. VP & CFO (Age 51)
- Mr. Wayne R. Swanton, Exec. VP of Global Operations (Age 50)
Who are Allergan's major shareholders?
Allergan's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Retirement Systems of Alabama (0.12%), Cacti Asset Management LLC (0.06%), Confluence Investment Management LLC (0.04%), Nisa Investment Advisors LLC (0.03%), Advisors Capital Management LLC (0.02%) and Arvest Bank Trust Division (0.02%). Company insiders that own Allergan stock include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado, Matthew M Walsh, Nesli Basgoz, Paul Bisaro and William Meury. View Institutional Ownership Trends for Allergan.
Which institutional investors are selling Allergan stock?
AGN stock was sold by a variety of institutional investors in the last quarter, including Confluence Investment Management LLC, Gateway Investment Advisers LLC, Gibraltar Capital Management Inc., Horan Capital Management, Gofen & Glossberg LLC IL, RNC Capital Management LLC, Vision Capital Management Inc. and Neville Rodie & Shaw Inc.. View Insider Buying and Selling for Allergan.
Which institutional investors are buying Allergan stock?
AGN stock was bought by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, Meeder Asset Management Inc., Contravisory Investment Management Inc., Cumberland Advisors Inc., Personal Capital Advisors Corp, Kempner Capital Management Inc., Diversified Trust Co and Steward Partners Investment Advisory LLC. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado and Matthew M Walsh. View Insider Buying and Selling for Allergan.
How do I buy shares of Allergan?
Shares of AGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Allergan's stock price today?
One share of AGN stock can currently be purchased for approximately $160.22.
How big of a company is Allergan?
Allergan has a market capitalization of $52.81 billion and generates $15.94 billion in revenue each year. The company earns $-4,125,500,000.00 in net income (profit) each year or $16.35 on an earnings per share basis. Allergan employs 17,800 workers across the globe.
What is Allergan's official website?
How can I contact Allergan?
Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]
MarketBeat Community Rating for Allergan (NYSE AGN)
MarketBeat's community ratings are surveys of what our community members think about Allergan and other stocks. Vote "Outperform" if you believe AGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
